Compare Costco Wholesale Corporation (COST) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Costco Wholesale Corporation trades at $921.51 (market cap $408.78B), while Regeneron Pharmaceuticals Inc trades at $653.1 (market cap $68.79B). The key difference: Costco Wholesale Corporation is far larger — about 5.9× Regeneron Pharmaceuticals Inc's market cap, and Costco Wholesale Corporation pays the higher dividend (0.64%). Which is the better fit depends on your goals.
| COST | REGN | |
|---|---|---|
Market Cap | $408.78B | $68.79B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $812.27 |
52-Week Low | $849.63 | $542.52 |
Enterprise Value | $396.92B | $62.74B |
Dividend Yield | 0.64% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $926.43, up 1.11% over 24h, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income of $8.10B, though Q1 2026 EPS missed expectations. The stock's valuation is elevated with a P/E of 46.37, while analyst consensus remains bullish with a $1,120 price target. Recent news highlights membership fee hikes and March sales growth of 11.3% year-over-year, indicating resilient consumer demand.
Outlook is mixed: robust membership model and sales trends support growth, but high valuation and technical bearishness pose near-term risks. Investors should weigh strong cash flow and analyst optimism against potential pullbacks from current levels. Key risks include competitive pressures and macroeconomic sensitivity, though institutional buying signals confidence.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
